Cell-to-Pack Patents: Who Leads, Where the Gaps Are 2026
- Filing has already peaked. Annual filings rose to 1,217 in 2022 before falling back toward 43 in the most recent partial year, a decline consistent with claim space that is filling in rather than opening up.
- No single filer dominates. The leader holds 14,120 records and the top 5 combined account for just 5.9% of the 742,879 records in scope — concentration is shallow across a very long tail.
- Momentum has stalled even among the biggest names. Several of the most active historical assignees show 0 filings in the latest year and year-on-year changes of -100%, a sign the field's centre of gravity is shifting.
What this landscape covers
Cell-to-Pack and Cell-to-Body integration collapses the traditional cell-module-pack hierarchy, embedding battery cells directly into the pack structure or the vehicle body to gain volumetric efficiency. That design shift touches crash load-path engineering, thermal propagation containment, joining and manufacturing methods, and serviceability — all of which show up as distinct claim clusters in the underlying patent data rather than as one unified technology.
The dataset spans 742,879 published records filed between 2015 and mid-2026, drawn from a search string built around cell and structural-battery-integration terms cross-referenced against volumetric efficiency, repair, crash load path, thermal propagation, manufacturing and joining language in titles and claims. Because publication lags filing by roughly 18 months, the most recent one or two years in any trend understate real filing activity.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
Two views of the same 742,879-record corpus: how filing activity has moved year over year, and which IPC subclasses the claims actually sit in.
A filing curve that has already turned over
Annual filings climbed from 839 in 2017 to a peak of 1,217 in 2022, then declined toward 43 in the latest, still-partial year. Read against the 18-month publication lag, the true 2025-2026 filing rate is understated, but the shape of the curve — rise, peak, decline — is unlikely to reverse into fresh acceleration.
Concentrated in batteries and semiconductor devices, with a biomedical tail
H01M (batteries, cells & fuel cells) and H01L (semiconductor devices) each account for roughly 0.8% of the 742,879 records in scope, the two largest single-class shares. The presence of C12N, A61K and C07K among the top classes reflects the search string's broad term overlap with biomedical and genetic-engineering filings rather than a genuine adjacency to vehicle battery integration, and should be read as corpus noise rather than a technology signal.
Shares are the percentage of the 742,879 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Cell-to-Pack and Cell-to-Body Integration with Eureka
This page is one run against one query. Ask Eureka your own question about cell-to-pack and cell-to-body integration and every answer comes back with the patent numbers behind it.
Try EurekaRepresentative and most-cited filings
Heating sheet of battery cell for thermal propagation evaluation and thermal propagation evaluation apparatus including the same
A thermal propagation evaluation apparatus with a housing that holds multiple battery cells in parallel and a heating sheet that heats a target cell to trigger and observe propagation behaviour. The heating sheet combines a cover shaped to one face of the cell with a heating coil, giving test engineers a repeatable way to induce and measure thermal propagation without damaging surrounding hardware.Filed by Samsung SDI, published 2026-08-13 — a test-and-validation patent rather than a pack-architecture claim.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO2013176772A1 | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcri… | 2,569 |
| 2 | US20140068797A1 | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcri… | 2,216 |
| 3 | US6838493B2 | Medical devices and applications of polyhydroxyalkanoate polymers | 1,832 |
| 4 | US6852330B2 | Reinforced foam implants with enhanced integrity for soft tissue repair and regeneration | 1,386 |
| 5 | US20050026157A1 | Use of chimeric nucleases to stimulate gene targeting | 1,272 |
| 6 | US20040119185A1 | Method for manufacturing opened-cell plastic foams | 932 |
| 7 | US5041138A | Neomorphogenesis of cartilage in vivo from cell culture | 848 |
| 8 | US6534084B1 | Porous tissue scaffoldings for the repair or regeneration of tissue | 572 |
| 9 | US5855619A | Biomatrix for soft tissue regeneration | 548 |
| 10 | WO2013074916A1 | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or HLA | 495 |
Citation counts favour older filings simply because they have had longer to accumulate citations inside the searched corpus; treat this table as a signal of influence, not of current technical importance. Several of the highest-cited records here relate to biomedical and genetic-engineering methods rather than battery integration, another artefact of the broad search terms.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing decision
Three patterns worth acting on before drafting new claims or scoping freedom-to-operate in this space.
Leadership is real but shallow
The leading assignee holds 14,120 records, and the top 5 combined account for 5.9% of all 742,879 records in scope — enough to matter, not enough to control the field. Freedom-to-operate work here has to clear a long tail of single- and low-filing entrants, not just the recognisable names.
The curve has already turned over
Filing activity peaked in 2022 and has fallen sharply since, even allowing for the 18-month publication lag understating the last two years. A declining curve after a clear peak usually means the core architecture claims are already staked out, and new filings are more likely to be refinements than fresh territory.
Historical leaders have gone quiet
More than one of the assignees with the deepest historical filing records shows zero filings in the latest year and a -100% year-on-year change, while at least one newer entrant holds flat, low-single-digit activity. That divergence is worth watching for signs of a shifting competitive set rather than assuming today's leaders will still lead next year.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to cell-to-pack and cell-to-body integration, with the prior art for and against each one.
Who is filing, and who has stopped
The ranking covers 100 companies counted by patent family, drawn from the full 742,879-record corpus. Read it alongside the momentum data — presence in the ranking does not mean continued activity.
A clear but not dominant top filer
The leading assignee's 14,120 records are the largest single share in the ranking, but that share still represents a small fraction of the total corpus, consistent with a technology area where architecture choices remain fragmented across many players rather than standardised around one design.
A steep drop-off after the top few
Record counts fall from the leader's 14,120 to 6,441 at fifth place and 4,353 at tenth, a steep early drop-off followed by a much longer, flatter tail across the remaining ranked companies.
Collaboration is limited and automotive-led
Only 10 co-assignee pairs appear in the data, and the strongest pairing links two automotive manufacturers rather than a cell maker and an automaker, suggesting joint IP work here is currently more common within vehicle-side engineering teams than across the cell-to-vehicle boundary.
| Assignee | Recent year | YoY |
|---|---|---|
| Contemporary Amperex Technology Co., Ltd. (CATL) | 5 | 0% |
| Toyota Motor Corporation | 0 | -100% |
| LG Energy Solution, Ltd. | 0 | -100% |
| Samsung Electronics Co., Ltd. | 0 | -100% |
| LG Electronics Inc. | 0 | — |
| LG Chem, Ltd. | 0 | — |
| SK Hynix Inc. | 0 | -100% |
| Sanyo Electric Co., Ltd. | 0 | — |
Where to take this next
The landscape points to specific follow-up work depending on whether the goal is freedom-to-operate, portfolio strategy or identifying acquisition targets.
Check freedom-to-operate against the long tail
With concentration this shallow, an FTO review that only checks the leading assignees will miss most of the risk. The 90 remaining ranked companies and the unranked tail carry the bulk of the 742,879 records.
Run a freedom-to-operate search in EurekaTrack which assignees are actually still filing
Several historically dominant filers show zero activity and -100% year-on-year change in the latest year. A portfolio strategy built on last decade's leaders may be watching the wrong companies.
Set up assignee monitoring in EurekaTest claims against the under-claimed branches
Repair access, post-crash disassembly and structural joining methods show thinner coverage than the core cell-integration claims. These are the branches most likely to still be open.
Explore white space in EurekaCommon questions about this landscape
The leading assignee in this dataset holds 14,120 records, well ahead of the next closest filers. However, the top 5 assignees combined account for only 5.9% of the 742,879 records in scope, and the top 10 combined reach just 9.4%. That means leadership is real at the individual-company level but the field overall is fragmented across a long tail of filers rather than controlled by a handful of firms.
No. Annual filings rose from 839 in 2017 to a peak of 1,217 in 2022, then declined sharply toward 43 in the most recent, still-partial year. Publication lags filing by roughly 18 months, so the last one to two years understate true activity, but the overall shape — a clear rise-and-fall rather than continued acceleration — suggests the core architecture claims are largely staked out.
Within this corpus, H01M (batteries, cells and fuel cells) and H01L (semiconductor devices) are the two largest IPC subclasses, each covering roughly 0.8% of the 742,879 records in scope. Because a record can carry multiple IPC classes, these shares sum to more than the record total, which is expected. Some of the classes that appear, such as those tied to genetic engineering and medicinal preparations, reflect broad overlap in the underlying search terms rather than genuine technical adjacency to vehicle battery integration.
The thinner branches in this dataset relate to repair and service access after cells are structurally integrated, post-crash pack disassembly methods, and structural adhesive joining approaches for load-bearing cells. These areas see far less claim density than core pack-integration architecture, likely because they sit downstream of the primary design decision and have historically been treated as secondary engineering problems rather than patentable innovation in their own right.
Several of the assignees with the deepest historical filing records in this corpus show zero filings in the latest year and a -100% year-on-year change, while at least one newer or smaller filer holds flat, low-single-digit activity. This could reflect a genuine pullback, a shift in filing strategy toward trade secret protection, or simply the publication lag masking filings not yet visible in the data. It is worth confirming with more recent internal filing records before concluding a competitor has exited the space.
Research Cell-to-Pack and Cell-to-Body Integration in depth with Eureka
Go past this page: query the whole cell-to-pack and cell-to-body integration corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.